Arecor Therapeutics plc

(“Arecor”, the “Company” or the “Group”)


Cambridge, UK, 27 August 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that Grant Thornton UK LLP (“Grant Thornton”) have been appointed as the Group’s auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.

NOTTINGHAM, U.K.; Aug. 25, 2021 – Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.

Biochemically defined and animal-free - Mussel Adhesive Protein based matrix (MAPtrix™) from AMSBIO provides a highly defined and controllable recombinant extracellular matrix (ECM) for cell culture, which can be tailored to the specific needs of particular cell types.

Sygnature Discovery Ltd has entered a collaboration with Epigeneron Inc., a leading Japanese bio-venture company that uses a unique cutting-edge technology to identify potential drug targets that regulate the expression of disease-related genes.

The two companies have signed a multi-project collaboration agreement to develop small molecule compounds of novel targets identified by Epigeneron’s unique technology, combined with the expertise of Sygnature’s highly experienced scientists.

Berlin-based FinTech start-up Nufin GmbH, which operates under the name Moss, has raised around 25 million Euros in a Series A-2 financing round including investments from Valar Ventures and other existing shareholders such as Cherry Ventures and Global Founders Capital. A team from the international law firm Taylor Wessing, led by Hamburg-based partner Jens Wolf, advised Nufin on all legal issues in connection with the Series A-2 financing round.

With Israeli startups continuing to break records in fundraising, the co-heads of our international Israel group, Josef Fuss and Nathan Krapivensky, outline potential opportunities in Europe and how they envisage the next phase of success for these businesses.

LexisNexis is profiling our partner and international co-head of Life Sciences and Healthcare Alison Dennis as part of its Meet the Experts section.

LINK Medical is pleased to announce that Maria Hortlund joins the Market Access team as a RWE Manager. Maria has over 15 years’ experience within RWE in the Nordics. She holds a PhD in Epidemiology and brings extensive knowledge of RWE-studies, from study concept to final report. She joins LINK Medical from the Karolinska Institute where she has had experience with national health registries, hospital data and biobanks in the Nordics and published 25 peer reviewed papers on cervical cancer screening.

AMSBIO is a knowledgeable supplier of products dedicated to exosome research that includes high quality reagents and kits that are quick, affordable and easy to use.

The latest addition to this portfolio is a new range of tools for isolating and purifying overall or specific exosome sub-populations from small volumes of sample in an efficient, faster and cheaper way. 

Click here to view the August edition of Dates for Your Diary.